Objective: To examine whether gene expression analysis of a large-scale Parkinson disease (PD) patient cohort produces a robust blood-based PD gene signature compared to previous studies that have used relatively small cohorts (#220 samples).
Parkinson disease (PD) is the second most common neurodegenerative disorder, characterized by dopaminergic neuron loss in the substantia nigra pars compacta leading to the onset of clinical parkinsonian symptoms. 1 Identifying biomarkers for PD such as blood-based biomarkers that can easily be obtained for analysis is thus highly attractive.
2 a-Synuclein, DJ-1, and uric acid have previously been studied as potential candidate blood-based biomarkers, 3 as well as epidermal growth factor and apolipoprotein A1 protein levels as respective biomarkers for PD cognitive performance 4 and age at onset. 5 Studying blood-based changes in mRNA gene expression presents an additional biomarker strategy for differentiating patients with IPD from healthy controls. 6 However, despite substantial work in this field, identifying a reliable and reproducible gene classification for PD has proved difficult. Of note, previous studies used relatively small cohorts, with the largest study previously undertaken using only 220 total samples, 7 which may have lacked sufficient power to identify a reliable PD gene signature. Here, we present whole-blood gene expression profiling of a large-scale cohort that generated a robust blood-based signature of 100 probes that mapped to 87 genes, which successfully classified samples as either IPD or healthy control. The genes within our IPD blood-based signature are functionally enriched for pathways, including mitochondrial metabolism and ubiquitination/proteasomal activity, 2 cellular processes previously implicated in PD. Our results demonstrate that a large dataset may be required to identify a blood-based IPD signature and to provide insight into PD pathophysiology.
METHODS Patient recruitment and clinical assessment.
We recruited 205 patients with IPD and 48 patients with other neurodegenerative diseases (NDDs; 27 patients with Huntington disease, and 21 with multiple system atrophy [MSA], corticobasal degeneration [CBD], progressive supranuclear palsy [PSP], or PD dementia [PDD]) to 2 tertiary referral centers in Europe (Luebeck, Germany, and Paris, France). In addition, 233 healthy controls were recruited, including nonconsanguineous controls from families of patients. All patients and controls from the German referral center were ethnically matched (German/white). All patients and controls from the French referral center were white except the following: 2 Africans, 2 Asians, and 1 English West Indies. Patients underwent rigorous clinical characterization, 8, 9 which included age at disease onset, Unified Parkinson's Disease Rating Scale score, Hoehn & Yahr score, and Montreal Cognitive Assessment (table e-1 at Neurology.org). Patients who had SPECT data available that showed scans without evidence of dopaminergic deficits were not included in the analysis. All patients in the IPD cohort were treated with dopaminergic medication and met United Kingdom Parkinson's Disease Society Brain Bank Criteria 10 except that positive family history was not regarded as an exclusion criterion. Patients who were suspected of having possible secondary causes for parkinsonism such as use of neuroleptic agents were excluded from the study. Patients with IPD were additionally evaluated for atypical signs, and patients meeting criteria for atypical PD syndromes (MSA, CBD, PSP, or PDD) were not included in the IPD cohort, were classified as atypical PD, and were included in the NDD cohort (e-Methods).
Standard protocol approvals, registrations, and patient consents. We obtained ethics approval at all participating sites, and all patients provided written informed consent.
RESULTS Identifying a blood-based signature for IPD.
To construct a robust blood-based classifier and gene signature to differentiate between patients with IPD and controls, we collected whole-blood gene expression profiles from 523 individuals. After quality control by preprocessing ( figure e-1) , the data contained profiles of 486 individuals: 205 patients with IPD, 233 healthy controls, and 48 patients with other NDDs (table e-1). All patients and controls were age matched for analysis. To perform our analysis, we partitioned the samples into 3 learning sets defined by similar age and sex distributions: a training set that contained 140 patients with IPD and 153 controls, a validation set that contained 35 patients with IPD and 40 controls, and a test set that contained 30 IPD, 40 controls, and all 48 NDD samples (table e-2). The training set was used for preprocessing and for testing feature selection and classification algorithms. The validation set was subsequently used as an initial test of the flow and to tune the size of the final gene signature, while the test set was used only once as a final independent validation ( figure 1A) .
To identify such a classifier, we first filtered out small batches (,10 samples) and probes with low expression across samples (log expression value ,6 in at least 80% of samples) because samples were collected from 2 different sites over 5 years (table e-3). We next used frozen Surrogate Variable Analysis (fSVA) 11 on the filtered data to reduce batch effects, producing a fixed model that could be used to reduce batch effects in independent samples derived from unknown batches. Using the fSVA-transformed data, we then selected k probes (for signature size k 5 10,20.200) with the highest difference in mean expression between patients with IPD and controls, which we denoted as the signature. Using these signature probes, we trained a linear support vector machine classifier and applied it to independent fSVA-transformed samples, producing a probability for each tested sample of being in the IPD class.
To validate the predictive value of our classifier, we performed leave-batch-out cross-validation on the training set by removing a batch from the data and allowing the classifier to identify an IPD signature that was based on the remaining samples. We found that the number of probes k 5 30 to 100 achieved results of comparable quality with high accuracy (figure e-2), with a maximal area under curve score obtained for the number of probes k 5 50 (area under curve 5 0.72). To further confirm the validity of our classifier for differentiating between patients with IPD and controls, we trained the classifier on the entire training set and then tested it on the validation set. When we again tested different numbers of probes (k 5 10,20.200), the top performance was achieved for probe number k 5 100 (figure 1C, black line). Thus, on the basis of the validation set analysis, we set the signature size k 5 100 to establish a signature of 100 probes to use in our IPD classifier.
To create the final signature, we trained the classifier on the union of the training and validation sets and identified a signature of 100 probes that mapped to 87 genes (table e-4). Of these, 64 genes were upregulated and 23 genes were downregulated, providing us with a unique blood-based signature capable of differentiating between patients with IPD and controls (figure 1B).
Validation on an independent test set. We subsequently tested the 87 gene signature on an independent test set (30 patients with IPD and 40 controls). We again observed high performance on this independent test set in differentiating between patients with IPD and controls (figure 1C, green line).
We further tested the robustness of our signature by splitting the independent test set into samples Figure 1 Identification of a blood-based gene signature for IPD (A) Overview of the analysis. Training process (left) involved preprocessing steps: removing unexpressed probes and small batches, reducing batch effects with fSVA, and identifying the most differential probes to learn the support vector machine classifier. Samples were partitioned into 3 datasets (DSs; right): training, validation, and test sets. The validation and training sets were used to evaluate the training process, and the validation set was additionally used to tune parameters (e.g., selection of the number of top probes). Finally, a classifier was learned using the data from the training and validation sets, and its performance was evaluated with the test set, which was excluded from all previous stages. from old batches that were present while learning the classifier (46 samples) and samples from new batches (24 samples). We observed that our signature differentiated between patients with IPD and controls in these independent test samples derived from either old batches (red line) or new batches (blue line) (figure 1D), further demonstrating the robustness of our 87-gene IPD signature. As expected, the signature reliably predicted an increased IPD probability for samples from the IPD cohort compared to healthy control samples (figure 2).
Application to other NDDs. To examine whether our signature was specific to patients with IPD, we applied our signature to 48 samples with other NDDs from the independent test set (27 patients with Huntington disease, 9 with MSA, 8 with PSP, 2 with CBD, and 2 with PDD). We found that the signature could not robustly differentiate between patients with NDD and controls but produced a weak signal that classified NDD samples as intermediates between IPD and control (figure 2). Our signature was still capable of successfully distinguishing IPD samples from the combined samples of controls and patients with NDD (figure e-3, purple line).
Network analysis of IPD signature. We next examined the cellular pathways associated with the 87 genes in our IPD blood-based signature by examining the functional enrichment of these genes using KEGG pathway analysis and Gene Ontology (GO) terms via EXPANDER. 12 Most notably, with the KEGG pathway analysis, the downregulated genes were enriched with genes in the PD pathway (COX4I1 [0.94], ATP5A1 [0.95], and VDAC3 [0.94]). With the use of GO terms, several processes were identified for downregulated genes, including genes related to nucleotide binding, negative regulation of nucleobasecontaining compound metabolic process, cellular catabolic process, and negative regulation of cellular process. In contrast, the upregulated genes were enriched for only 1 GO process (positive regulation of cellular metabolic process) (table 1) .
We also used GeneMANIA 13 to detect known interactions among the signature genes and identified additional genes connected to the signature genes (figure 3, black and gray nodes, respectively). The interactions identified included protein colocalization (dark blue line), similar protein-protein interaction networks (tan line), and similar pathways (light blue line). Twenty-two different biological functions (q , 0.05) were enriched within our signature genes (table 2), with energy derivation by oxidation of organic compounds the most enriched function. We also identified 3 functions that contained both upregulated and downregulated genes that represented different areas in the network: cellular respiration, protein polyubiquitination, and response to topologically incorrect protein. The diversity of these identified pathways suggests that various cellular processes may be altered in IPD. A larger subset of the genes identified in our IPD blood-based signature were related to metabolism, oxidation, and ubiquitination (table 2), key pathways that have previously been associated with PD pathogenesis. DISCUSSION In this study, we present a robust, unbiased blood-based signature differentiating between patients with IPD and controls. Using whole blood gene expression profiles of a large-scale cohort, we successfully identified a signature comprising 87 genes that classified participants into patients with IPD or healthy controls with high performance. Our signature differentiates between patients with IPD and controls in an independent test set not used in the training or validation process, suggesting that our signature may be equally successful in future cohorts.
Previous reports on PD signatures have used various signature sizes. In our study, we chose a signature size of 100 probes, which mapped to 87 genes, because it produced the most reliable signature for differentiating between patients with IPD and controls. In addition, because batch effects may severely influence data analysis and interpretation, 14 we both filtered out small batches (,10 samples) and applied fSVA 11 to the filtered data to produce a frozen model that reduced batch effects. Our IPD blood-based 87-gene signature was made up of 64 upregulated and 23 downregulated genes. In addition, network analysis identified enrichment of 22 biological functions using GeneMANIA and 1 upregulated pathway and 4 downregulated pathways using GO terms. These included PD-associated biological pathways such as ubiquitination/proteasomal activity, metabolic processes, and mitochondrial Table 2 GeneMANIA enrichment analysis on IPD signature function, suggesting that the use of a larger patient cohort may be beneficial for elucidating cellular mechanisms involved in PD pathophysiology. Genes linked to ubiquitination/proteasomal activity included E3 ubiquitin ligase Traf6 and the proteasome subunit alpha 7 (PSMA7), which were both downregulated. Of note, the ubiquitin proteasome system has been previously implicated in PD pathogenesis, 15 and mutations in the E3 ubiquitin ligase Parkin cause familial PD. 16 In addition, genes linked to mitochondrial function included 3 mitochondrialocalized genes (COX4I1, ATP5A1, and VDAC3), which were also downregulated and classified under the PD pathway by KEGG analysis. COX4I1 is the terminal enzyme of the mitochondrial respiratory chain, while ATP5A1 is a subunit of mitochondrial ATP synthase. VDAC3 encodes a voltage-dependent anion channel located on the outer mitochondrial membrane and has been implicated in recruiting Parkin to depolarized mitochondria for efficient autophagic degradation. 17 Indeed, autosomal recessive PD-linked mutations in Parkin, PINK1, and DJ-1 have been linked to defective mitochondrial homeostasis, 18 and cellular bioenergetics and mitochondrial electron transport genes are downregulated in laser-captured human dopaminergic neuron and substantia nigra PD transcriptomes, 19 suggesting that downregulation of key mitochondrial genes may be an important characteristic of an IPD blood-based signature.
Establishing a reliable and reproducible PD gene signature across different studies has proved to be challenging for the field. Indeed, comparison of signatures from 6 other blood-based PD studies 6, 7, [20] [21] [22] [23] shows that the only notable overlap between these previous studies was in the signatures from 2 studies. 7, 21 Several factors may contribute to the variability between previous blood-based PD gene signatures, 6 ,7,20-31 particularly between those published by different groups. 32 These include lack of replication in independent samples from multisite cohorts; lack of standardization in sample collection, processing, gene expression profiling, and bioinformatics analysis; and relatively small changes in gene expression levels, along with low signal-to-noise ratios. 2 In addition, samples across studies often derive from heterogeneous PD populations with different genetic backgrounds and varying rates of progression and disease stages. Moreover, batch effects and small cohort sizes further hinder the ability of the field to identify a reliable PD gene signature. Of note, the lack of reproducibility of exact gene signatures has been acknowledged as a prevalent problem across multiple diseases, although dissimilar signatures may produce equally useful predictive classifiers. [33] [34] [35] We propose that larger cohort sizes for gene signature studies are critical for establishing a reliable PD diagnostic signature and that a comprehensive understanding of the transcriptional landscape in patients with PD may ultimately require thousands of samples and the use of digital expression analysis platforms such as NanoString or RNA-seq. Of note, while our signature was trained to differentiate between PD and control samples, future signatures trained to differentiate between controls and different NDDs, including PD, will have obvious important diagnostic benefits. Ultimately, identifying robust and reliable PD gene expression signatures will be critical for establishing clinically accessible bloodbased biomarkers for presymptomatic PD and serving as effective readouts for the efficacy of future presymptomatic therapeutics.
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